9 documents found, page 1 of 1
European Journal of Heart Failure consensus statement. Heart failure pharmacoth...
Luedde, Mark; Agewall, Stefan; Ambrosio, Giuseppe; Bayes‐Genis, Antoni; Borghi, Claudio; Cerbai, Elisabetta; Dan, Gheorghe A.; Drexel, HeinzHeart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non-adherence and side effects. While rhythm control strategies in AF have gained attention...
Hospitalization of symptomatic patients with heart failure and moderate to seve...
Ponikowski, Piotr; Friede, Tim; von Bardeleben, Ralph Stephan; Butler, Javed; Shahzeb Khan, Muhammad; Diek, Monika; Heinrich, Jutta; Geyer, MartinBackground: For patients with functional mitral regurgitation (FMR) and symptomatic heart failure (HF), randomized trials of mitral transcatheter edge-to-edge repair (M-TEER) have produced conflicting results. Objectives: This study sought to assess the impact of M-TEER on hospitalization rates, and explore the effects of M-TEER on patients who did or did not have a history of recent HF hospitalizations before ...
Patiromer facilitates angiotensin inhibitor and mineralocorticoid antagonist th...
Pitt, Bertram; Anker, Stefan D.; Lund, Lars H.; Coats, Andrew J. S.; Filippatos, Gerasimos; Rossignol, Patrick; Weir, Matthew R.; Friede, TimBackground: Hyperkalemia (HK) is associated with suboptimal renin-angiotensin system (RAS) inhibitor and mineralocorticoid receptor antagonist (MRA) use in heart failure with reduced ejection fraction (HFrEF). Objectives: This study sought to assess characteristics and RAS inhibitor/MRA use in patients receiving patiromer during the DIAMOND (Patiromer for the Management of Hyperkalemia in Subjects Receiving RAA...
Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgita...
Anker, Stefan D.; Friede, Tim; von Bardeleben, Ralph Stephan; Butler, Javed; Khan, Muhammad Shahzeb; Diek, Monika; Heinrich, Jutta; Geyer, MartinAim: The RESHAPE-HF2 trial is designed to assess the efficacy and safety of the MitraClip device system for the treatment of clinically important functional mitral regurgitation (FMR) in patients with heart failure (HF). This report describes the baseline characteristics of patients enrolled in the RESHAPE-HF2 trial compared to those enrolled in the COAPT and MITRA-FR trials. Methods and results: The RESHAPE-HF...
Patiromer for the management of hyperkalemia in heart failure with reduced ejec...
Butler, Javed; Anker, Stefan D.; Lund, Lars H; Coats, Andrew J. S.; Filippatos, Gerasimos; Siddiqi, Tariq Jamal; Friede, Tim; Fabien, VincentAims: To investigate the impact of patiromer on the serum potassium level and its ability to enable specified target doses of renin-angiotensin-aldosterone system inhibitor (RAASi) use in patients with heart failure and reduced ejection fraction (HFrEF). Methods and results: A total of 1642 patients with HFrEF and current or a history of RAASi-related hyperkalemia were screened and 1195 were enrolled in the run...
Patient profiling in heart failure for tailoring medical therapy: a consensus d...
Rosano, Giuseppe M. C.; Moura, Brenda; Metra, Marco; Böhm, Michael; Bauersachs, Johann; Ben Gal, Tuvia; Adamopoulos, Stamatis; Abdelhamid, MagdyDespite guideline recommendations and available evidence, implementation of treatment in heart failure (HF) is poor. The majority of patients are not prescribed drugs at target doses that have been proven to positively impact morbidity and mortality. Among others, tolerability issues related to low blood pressure, heart rate, impaired renal function or hyperkalaemia are responsible. Chronic kidney disease plays...
Patiromer for the management of hyperkalaemia in patients receiving renin–angio...
Butler, Javed; Anker, Stefan D.; Siddiqi, Tariq Jamal; Coats, Andrew J. S.; Dorigotti, Fabio; Filippatos, Gerasimos; Friede, Tim; Göhring, Udo‐MichaelAims: In patients with current or a history of hyperkalaemia, treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K+ ) binder, may improve serum K+ levels and adherence to RAASi. Methods: The DIAMOND trial will enroll ∼820 patients with heart failure with reduced ejection fraction (HFrEF; ejection fraction ≤40%). Patients meeting the screeni...
Acute heart failure : lessons learned, roads ahead
Ferrari, Roberto; Bueno, Héctor; Chioncel, Ovidiu; Cleland, John G.; Stough, Wendy Gattis; Lettino, Maddalena; Metra, Marco; Parissis, John T.Acute heart failure remains a major challenge for clinicians and healthcare systems. The number of annual hospitalizations for acute heart failure is rising due to the aging of the general population and the increasing prevalence of heart failure. Heart failure is the leading cause of unplanned hospitalizations for patients older than 65 years in developed countries.1–4 These acute events impact the natural his...
Highlights of the 2009 scientific sessions of the European Society of Cardiology
Bax, Jeroen J.; Casadei, Barbara; Di Mario, Carlo; Fagard, Robert; Filippatos, Gerasimos; Fox, Keith A. A.; Metra, Marco; Nihoyannopoulos, PetrosThe annual congress of the European Society of Cardiology (ESC) was held in Barcelona, Spain, August 29 to September 2, 2009. The total attendance was 31,323 participants from 136 different countries. Excellent congress facilities hosted 237 pre-arranged sessions in 30 meeting rooms running in parallel, including several joint sessions in collaboration with other societies (e.g., the American College of Cardiol...